SULBACTAM

/static/temp/default.svg Search structure
Synonyms
Status
Molecule Category Free-form
ATC J01CG01
UNII S4TF6I2330
EPA CompTox DTXSID1023605

Structure

InChI Key FKENQMMABCRJMK-RITPCOANSA-N
Smiles CC1(C)[C@H](C(=O)O)N2C(=O)C[C@H]2S1(=O)=O
InChI
InChI=1S/C8H11NO5S/c1-8(2)6(7(11)12)9-4(10)3-5(9)15(8,13)14/h5-6H,3H2,1-2H3,(H,11,12)/t5-,6+/m1/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C8H11NO5S
Molecular Weight 233.25
AlogP -0.79
Hydrogen Bond Acceptor 4.0
Hydrogen Bond Donor 1.0
Number of Rotational Bond 1.0
Polar Surface Area 91.75
Molecular species ACID
Aromatic Rings 0.0
Heavy Atoms 15.0
Assay Description Organism Bioactivity Reference
Inhibitory activity against Branhamella catarrhalis 89001 Class-III BRO-1 type beta-lactamase enzyme b.catarr 0.025 ug.mL-1
Inhibitory activity against Bacteroides fragilis 88854 Class-I beta-lactamase enzyme Bacteroides fragilis 0.5 ug.mL-1
Inhibitory activity against Citrobacter freundii 87470 Class-I beta-lactamase enzyme Citrobacter freundii 0.2 ug.mL-1
Inhibitory activity against Enterobacter cloacae HC8 Class-I beta-lactamase enzyme type P99 Enterobacter cloacae 0.8 ug.mL-1
Compound was evaluated for beta-lactamase inhibition activity of Escherichia coli after 15 min of pre-incubation with the enzyme at 37 degree C Escherichia coli 800.0 nM
Inhibitory activity against Escherichia coli HA208 Class-III SHV-1 type beta-lactamase enzyme Escherichia coli 0.4 ug.mL-1
Inhibitory activity against Escherichia coli HA209 Class-V OXA-1 type beta-lactamase enzyme Escherichia coli 0.32 ug.mL-1
Inhibitory activity against Escherichia coli HA58R Class-III TEM-1 type beta-lactamase enzyme Escherichia coli 0.13 ug.mL-1
Inhibition constant (Ki) for TEM-1 beta-lactamase Escherichia coli 800.0 nM
Inhibitory activity against Klebsiella oxytoca HC7 Class-IV K1 type beta-lactamase enzyme Klebsiella oxytoca 0.4 ug.mL-1
Inhibitory activity against Proteus vulgaris HJ33C Class-I beta-lactamase enzyme Proteus vulgaris 0.08 ug.mL-1
Inhibitory activity against Staphylococcus aureus CJ8 beta-lactamase enzyme Staphylococcus aureus 0.8 ug.mL-1
Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 1.0 umol/L Bacillus cereus 2.0 %
Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 10.0 umol/L Bacillus cereus 40.0 %
Inhibitory activity at beta-lactamase I from Bacillus cereus expressed as percent inhibition of beta-lactam hydrolysis at a concentration of 100.0 umol/L Bacillus cereus 77.0 %
Inhibitory activity against cephalosporinase from Proteus vulgaris TH-147 using cephalexin (40 uM) as a substrate Proteus vulgaris 800.0 nM
Inhibition of Bacillus clausii NR beta-lactamase BCL1 expressed in Escherichia coli BL21 (DE3) Bacillus clausii 75.0 nM
Inhibition of Pseudomonas aeruginosa GES-13 beta lactamase Pseudomonas aeruginosa 370.0 nM
Inhibition of Escherichia coli Inhibitor-resistant beta-lactamase SHV-56 Escherichia coli 300.0 nM
Inhibition of recombinant beta-lactamase RTG3 expressed in Escherichia coli TOP10 by nitrocefin hydrolysis assay None 200.0 nM
Inhibition of beta-lactamase SHV-4 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation None 260.0 nM
Inhibition of beta-lactamase CTX-M-15 assessed as nitrocefin hydrolysis after 5 mins enzyme-compound preincubation None 230.0 nM
Inhibition of Beta-lactamase GES-2 E104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry None 500.0 nM
Inhibition of Beta-lactamase GES-13 K104, N170 mutant preincubated for 5 mins before substrate addition using cephalothin substrate by spectrophotometry None 300.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 15.66 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 13.47 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 7.736 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.03 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.02 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.02 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus -0.03 %

Related Entries

Cross References

Resources Reference
ChEBI 9321
ChEMBL CHEMBL403
DrugBank DB09324
DrugCentral 2492
FDA SRS S4TF6I2330
Guide to Pharmacology 10769
KEGG C07770
PDB 0RN
PubChem 130313
SureChEMBL SCHEMBL47781
ZINC ZINC000000897244
CONTENTS